How Big A Blow To Biogen Is NICE 'No' For Spinraza?
The US biotech is aghast that the cost-effectiveness committee for England, Wales and Northern Ireland is minded to reject its effective but pricey SMA therapy which has gained blockbuster status already on strong sales elsewhere in Europe and the US.
You may also be interested in...
Vertex says it will not file data on its cystic fibrosis drug Symkevi (tezacaftor/ivacaftor) until the UK's NICE changes the way it assesses drugs.
Speaking to Scrip, Steven Baert, chief people and organization officer at Novartis, said that a company’s response to coronavirus reveals its real identity and will shape its future.
The UK biotech's CEO tells Scrip that Izana's objective is to treat rapidly deteriorating COVID-19 patients before ICU admission and prior to ventilation.